Posted by Mie University and Nagoya University has jointly developed an Indocyanine / β-cyclodextrin conjugate suitable for ureter visualization in patients undergoing laparoscopic/minimally invasive colorectal surgery. Astellas Pharma Inc. has acquired exclusive development and marketing rights worldwide (the designation of the compound is ASP5354). A recent clinical trial investigated the safety, tolerability and the pharmacokinetics of ASP5354 in participants undergoing laparoscopic/minimally invasive surgery.
https://classic.clinicaltrials.gov/ct2/show/NCT04238481
ASP5354 fluoresces upon excitation with a particular wavelength of near-infrared light. When administered intravenously, ASP5354 is primarily and rapidly excreted by the kidneys and provides the surgeon with visualization of the ureter(s) during surgery through the use of a near-infrared fluorescence (NIR-F) medical device.
For further reading:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276870/pdf/41598_2023_Article_37025.pdf
The details of the synthesis/characterization of the cyclodextrin derivative may be accessed here:
https://static-content.springer.com/esm/art%3A10.1038%2Fs41598-023-37025-z/MediaObjects/41598_2023_37025_MOESM1_ESM.pdf